Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$10.07
+1.0%
$10.78
$4.75
$41.72
$104.87M1.3223,601 shs10,745 shs
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
$14.48
+28.2%
$15.01
$5.26
$86.00
$33.84M0.683,210 shs3,045 shs
PARK
Park Dental Partners
$18.87
-3.0%
$19.10
$9.53
$22.67
$87.86MN/A33,405 shs9,530 shs
Exagen Inc. stock logo
XGN
Exagen
$4.68
+6.6%
$4.41
$2.59
$12.23
$106.06M2.02197,878 shs508,063 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
+1.00%-5.53%+38.90%-51.23%+114.26%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
+21.55%+36.53%-9.14%+149.79%-77.01%
PARK
Park Dental Partners
-3.03%-9.06%+3.45%+4.31%+1,886,999,900.00%
Exagen Inc. stock logo
XGN
Exagen
+6.61%+13.04%+3.08%+60.82%-33.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$10.07
+1.0%
$10.78
$4.75
$41.72
$104.87M1.3223,601 shs10,745 shs
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
$14.48
+28.2%
$15.01
$5.26
$86.00
$33.84M0.683,210 shs3,045 shs
PARK
Park Dental Partners
$18.87
-3.0%
$19.10
$9.53
$22.67
$87.86MN/A33,405 shs9,530 shs
Exagen Inc. stock logo
XGN
Exagen
$4.68
+6.6%
$4.41
$2.59
$12.23
$106.06M2.02197,878 shs508,063 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
+1.00%-5.53%+38.90%-51.23%+114.26%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
+21.55%+36.53%-9.14%+149.79%-77.01%
PARK
Park Dental Partners
-3.03%-9.06%+3.45%+4.31%+1,886,999,900.00%
Exagen Inc. stock logo
XGN
Exagen
+6.61%+13.04%+3.08%+60.82%-33.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1.00
SellN/AN/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
2.00
Hold$55.00279.76% Upside
PARK
Park Dental Partners
2.75
Moderate Buy$21.7515.26% Upside
Exagen Inc. stock logo
XGN
Exagen
2.90
Moderate Buy$9.1194.68% Upside

Current Analyst Ratings Breakdown

Latest EUDA, BNR, XGN, and PARK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
Reiterated RatingSell (D-)
6/24/2026
Exagen Inc. stock logo
XGN
Exagen
Initiated CoverageBuy$8.00
6/24/2026
Exagen Inc. stock logo
XGN
Exagen
UpgradeStrong-Buy
6/9/2026
PARK
Park Dental Partners
UpgradeSell (E)Sell (E+)
6/3/2026
PARK
Park Dental Partners
DowngradeStrong-BuyHold
5/27/2026
PARK
Park Dental Partners
DowngradeSell (E+)Sell (E)
5/18/2026
PARK
Park Dental Partners
UpgradeHoldStrong-Buy
5/12/2026
PARK
Park Dental Partners
UpgradeSell (E)Sell (E+)
5/12/2026
Exagen Inc. stock logo
XGN
Exagen
DowngradeSell (D-)Sell (E+)
5/12/2026
Exagen Inc. stock logo
XGN
Exagen
Lower Price TargetBuy$9.00 ➝ $8.00
5/8/2026
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
DowngradeSell (D)Sell (E+)
(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$77.16M1.37N/AN/A$7.28 per share1.38
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
$6.82M6.35N/AN/A($2.26) per share-6.41
PARK
Park Dental Partners
$248.15M0.34$4.26 per share4.43$5.33 per share3.54
Exagen Inc. stock logo
XGN
Exagen
$66.57M1.70N/AN/A$0.77 per share6.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$7.92M-$0.82N/AN/AN/A-11.57%-10.98%-7.33%9/2/2026 (Estimated)
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
-$2.77MN/AN/AN/AN/AN/AN/AN/A7/28/2026 (Estimated)
PARK
Park Dental Partners
-$360K$0.7425.5024.83N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
-$19.95M-$0.89N/AN/AN/A-29.49%-94.37%-28.96%8/4/2026 (Estimated)

Latest EUDA, BNR, XGN, and PARK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Exagen Inc. stock logo
XGN
Exagen
-$0.19N/AN/AN/A$17.80 millionN/A
7/28/2026N/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
$0.40N/AN/AN/A$9.61 millionN/A
6/9/2026Q1 2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$2.2884-$0.20+$2.0884-$0.25$19.21 million$15.66 million
5/13/2026Q1 2026
PARK
Park Dental Partners
$0.19$0.44+$0.25-$0.09N/A$62.70 million
5/11/2026Q1 2026
Exagen Inc. stock logo
XGN
Exagen
-$0.24-$0.17+$0.07-$0.17$16.41 million$17.31 million
5/5/2026Q4 2025
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
-$1.20-$0.44+$0.76-$0.44$3.90 million$1.92 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
N/AN/AN/AN/AN/A
PARK
Park Dental Partners
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
0.06
3.05
2.81
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
N/A
0.18
0.18
PARK
Park Dental Partners
0.38
1.07
1.07
Exagen Inc. stock logo
XGN
Exagen
1.67
3.47
3.47

Institutional Ownership

CompanyInstitutional Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.03%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
4.35%
PARK
Park Dental Partners
N/A
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.30%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
N/A
PARK
Park Dental Partners
10.56%
Exagen Inc. stock logo
XGN
Exagen
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1,39010.52 million7.33 millionNot Optionable
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
22.99 millionN/ANot Optionable
PARK
Park Dental Partners
1,2124.52 million4.04 millionN/A
Exagen Inc. stock logo
XGN
Exagen
22024.16 million21.65 millionOptionable

Recent News About These Companies

Exagen Earnings Call Highlights Growth Amid Key Risks
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Inc. Reports First Quarter 2026 Results
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$10.07 +0.10 (+1.00%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$10.20 +0.13 (+1.29%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

EUDA Health stock logo

EUDA Health NASDAQ:EUDA

$14.48 +3.18 (+28.17%)
Closing price 07/20/2026 03:58 PM Eastern
Extended Trading
$13.72 -0.77 (-5.29%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.

Park Dental Partners NASDAQ:PARK

$18.87 -0.59 (-3.03%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$19.05 +0.18 (+0.95%)
As of 07/20/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

As a dental resource organization (“DRO”) operating through Park Dental Partners, Inc., and subsidiaries, we provide comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to our affiliated general and multi-specialty dental practices (which are not legal subsidiaries) throughout Minnesota and Wisconsin. Our network of affiliated dental practices employs over 200 dentists across 84 practice locations and was ranked as one of Minnesota’s largest private companies by revenue by the Minneapolis/St Paul Business Journal in June 2025. Our clinical support team includes over 900 hygienists, dental assistants, and patient care coordinators that support affiliated dentists in operating their dental practices. Our network of affiliated dental practices has been operating for over fifty years, beginning with the establishment of the general dentistry group in 1972. The mission of our affiliated dental practices since inception has been to ensure patients enjoy the benefits of a lifetime of good oral health. This mission continues to be the driving force behind our organization today. Our network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30 years, with automatic 5-year renewals. We have established a significant footprint and brand awareness in our current markets. Our revenues, derived primarily from our affiliated dental practices’ provision of dental services, were approximately $183.3 million and $172.9 million for the nine months ended September 30, 2025 and 2024, respectively, and were approximately $229.8 million and $223.5 million for the years ended December 31, 2024 and 2023, respectively. Our material revenues are comprised of dental services, which includes the consolidated revenues of our affiliated dental practices. Dental services are provided to patients, who typically pay for services through private insurance plans, government insurance plans, or directly. Approximately 91% and 93% of total revenues for each of the nine months ended September 30, 2025, and 2024, respectively, and approximately 93% of total revenues for each of the years ended December 31, 2024 and 2023, respectively, were derived from patients with private insurance or government sponsored plans. Dental care patients tend to be price-sensitive because many pay for a significant portion of their dental expenses on an out-of-pocket basis. We have steadily grown by adding new dentists and team members, expanding existing practices, implementing operating efficiencies, and by acquiring existing practices. Our organic expansion includes opening de novo practices, which are new practice locations opened with our affiliated dentists in existing or new markets. Since the start of calendar 2014 we have acquired 40 practices and opened 11 de novo practices. On average, de novo practices are cash flow positive within approximately six months, meaning that the practice location monthly Gross Margin excluding depreciation is positive. Of the 11 de novo practices opened since 2014, more than 80% were cash flow positive within six months. We attribute this success to our established model that streamlines day-to-day dental practice operations by providing key business and administrative resources, allowing dentists and team members to focus on patient care. We plan to expand our existing general and multi-specialty dental brands, establishing a group of successful, respected dental practices. Dentists hold a majority interest in our organization, which we believe is a key differentiator between our model and those of our competitors. Our model provides our affiliated dentists with significant organizational input because our affiliated dentists, who are majority shareholders in the business, are directly involved in our governance through their right to appoint three directors to the Board of Directors. We believe this right helps ensure that our affiliated dentists maintain a professional voice in governance that helps focus the organization on ensuring patients enjoy the benefits of a lifetime of good oral health. We believe this compelling model allows for greater input and provides enhanced stewardship for dentists, which assists with attracting and retaining dental professionals and serves as a catalyst for future growth. By contrast, we believe traditional dental organization ownership structures, many of which are funded by private equity, introduce constraints and concessions that limit dentists’ clinical autonomy and can restrict or omit dentists’ professional voice in governance. --- Our affiliated dental practices have been in operation since the founding of Park Dental in 1972. In May 2023, the owners of our affiliated dental practices established a dental resource organization 100% owned by dentists and management, through the creation of Park Dental Partners, Inc. and transitioned to the new operating structure on October 1, 2023. Park Dental Partners, Inc was incorporated in the state of Minnesota in 2023 to act as a dental resource organization for the operating affiliated dental practices. Our principal executive offices are located in Roseville, Minnesota.

Exagen stock logo

Exagen NASDAQ:XGN

$4.68 +0.29 (+6.61%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$4.76 +0.09 (+1.82%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.